About
Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Subsequent to the acquisition of Medistem by Intrexon, in a deal worth $26 million, Dr. Ichim was brought on to the parent company in its cell engineering unit as Vice President of Cellular Therapy. Thomas Ichim hopes to greatly add to the value of Batu Biologics by leveraging his existing contacts and experience in product development, regulatory filings, and business development.
Position in the VCSift Database
- • 2 investors hold the President & CSO role in VCSift. Thomas Ichim is one of them.
- • 273 investors are based in Phoenix, Arizona, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Phoenix, US
Contact Information
Find more investors like Thomas
Search Investors